SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas long-delayed Roadster reveal is driving attention, with traders debating whether it will deliver concrete production or performance details or amount to another sell-the-news event. Speculation that the event could bring a TeslaSpaceX merger announcement is also circulating, but remains unconfirmed; broader market weakness is adding pressure.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Reports of declining Truth Social traffic and DJTs prolonged selloff are driving bearish discussion, with many traders questioning the companys business prospects amid contentious political and economic headlines. A smaller bullish camp points to a possible rebound or TAE Technologies deal, but the deal is discussed speculatively.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

Renewed buying in enterprise softwareframed by traders as a rotation out of AI-chip stockshas lifted NOW amid optimism about its AI-agent governance and workflow products, including the AI Passport launch. Bulls see a breakout taking shape, while skeptics point to repeated resistance and sharp reversals that have made gains difficult to hold.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys extended rally and approach of its quarterly results are driving attention, with traders pointing to strong momentum and the Meta Muse checkout partnership as potential growth support. Bulls see room for the run to continue, while others warn the shares look overbought and could pull back after the sharp advance.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dells sharp selloff followed Barclays downgrade, which questioned whether enterprise AI spending is accelerating and argued that higher component prices may be contributing to revenue growth. Traders are split between seeing the drop as an overdone reaction and viewing it as a reassessment of lofty AI expectations, with some blaming the analyst call for the decline.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassians strong quarterly results and cloud outlook, alongside growing interest in its AI products, have fueled a sharp rally and renewed optimism about a broader SaaS recovery. Bulls see evidence that AI can benefit rather than displace software platforms, while cautious traders warn the move may be overextended and vulnerable to profit-taking.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas new U.S. beverage partnership with KFC, replacing Pepsi at its restaurants beginning in 2027, is drawing attention as a competitive win that could expand Cokes food-service presence. Traders largely view the switch positively for KO and as a setback for Pepsi, while some wonder whether the change will extend to other Yum! Brands chains.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Concerns that Pharvaris positive deucrictibant XR data could intensify competition for BioCrysts HAE drug Orladeyo are dominating discussion, alongside a bearish analyst reassessment of its revenue outlook. The selloff has frustrated shareholders and fueled calls to sell the company, while some traders argue the rival treatment is still years from launch and point to navenibart as longer-term potential.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Treasury yield swings and expectations for a higher-for-longer Fed path are driving discussion, with persistent inflation and possible rate hikes cited as pressure on intermediate-term bond prices. Traders are largely bearish on IEF, though some see recent yield pullbacks as a chance for a bond rebound.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Hot inflation readings, renewed rate-hike worries and concerns about debt-heavy AI spending and semiconductor weakness have fueled sharp swings in QQQ; traders are split between expecting more tech-led losses and viewing dip-buying and short covering as signs of a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

Encouraging early VS-7375 data, including a 50% confirmed response rate in a small second-line pancreatic cancer cohort and a planned Phase 3 path, are driving attention. Traders are weighing the drugs potential against the need to confirm durability and its competitive edge, while the share offering has raised dilution concerns.

The move appears tied to encouraging VS-7375 trial results, including a 50% confirmed response rate in second-line metastatic pancreatic cancer, and multiple analyst price-target increases. Traders are also focusing on additional GenFleet combination data in colorectal and pancreatic cancer.

Equity

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 


Companies Entering High-Stakes Market Moments

The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.

Wall Street’s Next Movers

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.read more...

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire's $330M investment. Liquidia and Verastem also posted strong gains.read more...

Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know 

Verastem reported positive results from its ongoing Phase 1/2 trial involving patients with advanced cancers carrying the KRAS G12D mutation.


Verastem Oncology Prices $250 Mln Stock, Warrant Offering; Pre-market Shares Up

(RTTNews) - Biopharmaceutical company Verastem Oncology (VSTM), announced on Wednesday that it has priced an underwritten offering of 30.94 million shares at $8 each and pre-funded warrants for 0.31 million shares at $7.9999 each, raising about $250 million...

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its...

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will...

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive initial efficacy and updated safety and tolerability data in first multi-tumor clinical data update from the ongoing...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Extremely Bullish Sentiment

50bps hike

25bps hike

No change

Rate cut

September CPI rose 0.6% from the prior month to 3.7% annually, while producer prices jumped 6.3% year-over-year, the biggest gain since 2022, putting the Federal Reserve's October 27-28 meeting squarely in focus after its first rate hike in three years last month. What does the Fed do at its October meeting? Vote and explain your reasoning in the comments.

September CPI hit 3.7% and PPI jumped 6.3%, both hotter than expected. What does the Fed do at its October meeting?

Stocktwits

Stocktwits Polls

Investors are celebrating stellar clinical data from the KRAS G12D inhibitor trial, which showed strong response rates in pancreatic cancer.

Anticipation of a strategic acquisition is mounting as traders connect the leadership change to historical pharma buyout playbooks.

While clinical results excite the bulls, a $250M secondary offering has sparked intense debate over shareholder value versus long-term funding.

High volumes and massive interest in price movement have fueled aggressive bets against short sellers aiming to trigger a forced cover.

Current Price	$9.23
Prev Close	$7.71
Open	$8.04
Dividend Yield	0.00%
50-Day Moving Average	$7.49
Beta	1.27
Avg. Volume	2.47M
PE Ratio	-3.13

52-Week High	$10.82
52-Week Low	$3.43
Market Capitalization	$698.24M
EPS (Annual)	-$3.02
Price to Book	13.96
Revenue Per Employee	$303,078.43

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM Fundamentals